The Mayo Clinic, a leading US hospital group, has launched Mayflower BioVentures, a cell and gene therapy accelerator, in partnership with Hibiscus BioVentures and Innoforce Pharmaceuticals. The venture aims to translate lab technologies into viable therapies for unmet patient needs, with leadership from Mayo Clinic clinicians and Hibiscus executives.
Collaboration Details
Mayflower BioVentures will focus on forming companies around innovative cell and gene therapies. Mayo Clinic, known for its regenerative biotherapeutics research, will contribute clinical expertise, while Hibiscus BioVentures brings operational and investment experience. Innoforce Pharmaceuticals, based in Hangzhou, China, will provide end-to-end contract development and manufacturing (CDMO) capabilities, including GMP production of plasmid DNA, RNA, viral vectors, and cell products.
Leadership and Financials
The venture will be led by Mayo Clinic’s clinical experts and Hibiscus executives. All three partners have financial stakes in Mayflower, with Mayo Clinic reinvesting any revenues into patient care, education, and research.
Mayo Clinic’s Portfolio
Mayo Clinic has developed next-generation immune modulators and novel cell/gene therapies, operating the Center for Regenerative Biotherapeutics to integrate new technologies into clinical practice. The partnership with Hibiscus and Innoforce aims to scale these innovations globally.-Fineline Info & Tech
